Epigenomics AG Licenses Biomarker for Development of Prostate Cancer Test to Quest Diagnostics
ots.CorporateNews transmitted by euro adhoc. The issuer is responsible for the content of this announcement. cooperations/Molecular Diagnostics Berlin, Germany and Seattle, WA, U.S.A. (euro adhoc) - February 25, 2009 - Epigenomics AG (Frankfurt, Prime Standard: ECX), a cancer molecular diagnostics company, today announced that it has entered into a ...